Literature DB >> 17541396

BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

L Legros, S Hayette, F E Nicolini, S Raynaud, K Chabane, J-P Magaud, J-P Cassuto, M Michallet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17541396     DOI： 10.1038/sj.leu.2404772

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

Review 1.  Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.

Authors:  Y Chen; C Peng; C Sullivan; D Li; S Li
Journal:  Leukemia       Date:  2010-06-24       Impact factor: 11.528

2.  Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

Authors:  Franck Emmanuel Nicolini; Grzegorz W Basak; Simona Soverini; Giovanni Martinelli; Michael J Mauro; Martin C Müller; Andreas Hochhaus; Charles Chuah; Inge H Dufva; Giovanna Rege-Cambrin; Giuseppe Saglio; Mauricette Michallet; Hélène Labussière; Stéphane Morisset; Sandrine Hayette; Gabriel Etienne; Eduardo Olavarria; Wei Zhou; Senaka Peter; Jane F Apperley; Jorge Cortes
Journal:  Blood       Date:  2011-09-16       Impact factor: 22.113

Review 3.  Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Cong Peng; Con Sullivan; Dongguang Li; Shaoguang Li
Journal:  Anticancer Agents Med Chem       Date:  2010-02       Impact factor: 2.505

Review 4.  Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-20

5.  Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Authors:  Jorge Cortes; Jeff H Lipton; Delphine Rea; Raghunadharao Digumarti; Charles Chuah; Nisha Nanda; Annie-Claude Benichou; Adam R Craig; Mauricette Michallet; Franck E Nicolini; Hagop Kantarjian
Journal:  Blood       Date:  2012-08-15       Impact factor: 22.113

6.  Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Authors:  Franck E Nicolini; Michael J Mauro; Giovanni Martinelli; Dong-Wook Kim; Simona Soverini; Martin C Müller; Andreas Hochhaus; Jorge Cortes; Charles Chuah; Inge H Dufva; Jane F Apperley; Fumiharu Yagasaki; Jay D Pearson; Senaka Peter; Cesar Sanz Rodriguez; Claude Preudhomme; Francis Giles; John M Goldman; Wei Zhou
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

7.  Synthesis of antiproliferative Cephalotaxus esters and their evaluation against several human hematopoietic and solid tumor cell lines: uncovering differential susceptibilities to multidrug resistance.

Authors:  Joseph D Eckelbarger; Jeremy T Wilmot; Matthew T Epperson; Chandar S Thakur; David Shum; Christophe Antczak; Leonid Tarassishin; Hakim Djaballah; David Y Gin
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

8.  Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.

Authors:  Elias Jabbour; Hagop Kantarjian; Dan Jones; Megan Breeden; Guillermo Garcia-Manero; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Jorge Cortes
Journal:  Blood       Date:  2008-04-10       Impact factor: 22.113

9.  Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.

Authors:  Jorge E Cortes; Franck E Nicolini; Meir Wetzler; Jeffrey H Lipton; Luke Akard; Adam Craig; Nisha Nanda; Annie-Claude Benichou; Janis Leonoudakis; H Jean Khoury; Andreas Hochhaus; Michele Baccarani; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-17

10.  Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.

Authors:  Y Chen; Y Hu; S Michaels; D Segal; D Brown; S Li
Journal:  Leukemia       Date:  2009-03-26       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.